Analyst Tracker/Mitchell Kapoor

Mitchell Kapoor

Q: How accurate are Mitchell Kapoor's stock ratings?

About 53% of Mitchell's ratings were profitable over a one-year hold, with an average return of +5.1% per rating, measured by 13Foresight from historical prices.

Q: How is Mitchell ranked?

Mitchell Kapoor is ranked #1427 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

H.C. Wainwright

Wall Street Analyst

★★★☆☆

#1427

on 13Foresight · ranked by our own returns

54%

Success Rate

+5.2%

Average Return

58 of 107 calls profitable · +2.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 54% of Mitchell Kapoor's ratings turned a profit when each position was held for 1 year — averaging +5.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

246 Buy 33 Hold 14 Sell

Mitchell's Stock Coverage 41 ratings · 2026-08-12

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
DMRA Damora Therapeutics	Aug 11, 2026	BUY	Strong Buy -4.7% avg upside 20 analysts	$45.00 48.12% Upside	·	·
ALMS Alumis Inc.	Aug 11, 2026	HOLD	Strong Buy +47.3% avg upside 11 analysts	$25.00 1.42% Downside	+0.0%	·
PALI Palisade Bio	Aug 11, 2026	BUY	Strong Buy +1122.9% avg upside 16 analysts	$7.00 227.20% Upside	+0.0%	·
LEGN Legend Biotech	Aug 11, 2026	BUY	Strong Buy +195.3% avg upside 27 analysts	$65.00 197.77% Upside	·	·
SE:SOBI Swedish Orphan Biovitrum AB	Aug 10, 2026	BUY	Strong Buy +1.5% avg upside 7 analysts	$575.00 30.26% Upside	·	·
EVMN Evommune, Inc.	Aug 07, 2026	HOLD	Strong Buy +168.9% avg upside 12 analysts	—	+0.9%	·
GENB Generate Biomedicines, Inc.	Aug 07, 2026	BUY	Strong Buy +77.4% avg upside 6 analysts	$25.00 75.23% Upside	+0.0%	·
BMRN BioMarin Pharmaceutical	Aug 07, 2026	HOLD	Strong Buy +36.7% avg upside 52 analysts	$60.00 13.67% Downside	+10.0%	·
HALO Halozyme	Aug 07, 2026	BUY	Strong Buy -36.6% avg upside 20 analysts	$115.00 12.13% Upside	-1.3%	·
NTLA Intellia Therapeutics	Aug 07, 2026	BUY	Buy +221.7% avg upside 37 analysts	$25.00 107.92% Upside	+1.3%	·
AVTX Avalo Therapeutics	Aug 07, 2026	BUY	Strong Buy +167.3% avg upside 20 analysts	$30.00 54.01% Upside	+6.0%	·
RNAC Cartesian Therapeutics	Aug 07, 2026	BUY	Strong Buy +268.0% avg upside 19 analysts	$25.00 191.24% Upside	+0.0%	·
KRRO Korro Bio	Aug 07, 2026	BUY	Strong Buy +102.3% avg upside 19 analysts	$15.00 12.54% Upside	+0.5%	·
LYEL Lyell Immunopharma	Aug 07, 2026	BUY	Strong Buy +87.4% avg upside 12 analysts	$45.00 202.42% Upside	-2.6%	·
RNA Atrium Therapeutics, Inc.	Aug 06, 2026	BUY	Strong Buy +164.2% avg upside 5 analysts	$25.00 103.75% Upside	+1.3%	·
SRPT Sarepta Therapeutics	Aug 06, 2026	SELL	Buy +233.1% avg upside 49 analysts	$5.00 72.63% Downside	-0.0%	·
EDIT Editas Medicine	Aug 06, 2026	BUY	Buy +369.4% avg upside 33 analysts	$5.00 69.56% Upside	-3.1%	·
TYRA Tyra Bioscience	Aug 05, 2026	BUY	Strong Buy +75.8% avg upside 17 analysts	$45.00 78.76% Upside	+2.1%	·
IONS Ionis Pharmaceuticals	Aug 05, 2026	BUY	Strong Buy +42.3% avg upside 43 analysts	$115.00 107.42% Upside	+5.1%	·
SMMT Summit Therapeutics	Aug 05, 2026	HOLD	Strong Buy +89.3% avg upside 27 analysts	—	+9.9%	·
CRSP Crispr Therapeutics AG	Aug 05, 2026	BUY	Buy +40.2% avg upside 41 analysts	$80.00 47.99% Upside	+2.9%	·
INCY Incyte	Aug 03, 2026	BUY	Buy -11.2% avg upside 47 analysts	$150.00 23.89% Upside	+2.0%	·
ORKA Oruka Therapeutics	Aug 03, 2026	BUY	Strong Buy +20.5% avg upside 16 analysts	$120.00 14.74% Upside	+10.4%	·
CBIO Crescent Biopharma	Jul 31, 2026	HOLD	Strong Buy +31.8% avg upside 17 analysts	—	+16.4%	·
MGTX Meiragtx Holdings	Jul 08, 2026	BUY	Strong Buy +99.4% avg upside 13 analysts	$20.00 53.21% Upside	-8.0%	·
NGNE Neurogene	Jun 30, 2026	BUY	Strong Buy +40.6% avg upside 23 analysts	$70.00 95.53% Upside	+13.5%	·
KYTX Kyverna Therapeutics, Inc.	Jun 04, 2026	BUY	Strong Buy +241.9% avg upside 7 analysts	$25.00 211.65% Upside	-0.8%	·
IPSC Century Therapeutics	May 26, 2026	BUY	Strong Buy +161.3% avg upside 11 analysts	$5.00 142.73% Upside	-9.7%	·
CTMX CytomX Therapeutics	May 11, 2026	BUY	Strong Buy +214.5% avg upside 21 analysts	$11.00 218.82% Upside	-10.9%	·
LXEO Lexeo Therapeutics, Inc.	Jan 13, 2026	BUY	Strong Buy +307.1% avg upside 11 analysts	$10.00 109.14% Upside	-38.4%	·
TIL Instil Bio	Jan 08, 2026	HOLD	Buy +345.4% avg upside 8 analysts	—	+1.4%	·
BOLD Boundless Bio Inc.	Oct 24, 2025	BUY	Hold +227.3% avg upside 11 analysts	$4.00 45.46% Upside	+98.0%	·
MGX Metagenomi, Inc.	Oct 22, 2025	BUY	Strong Buy +593.3% avg upside 8 analysts	$7.00 478.50% Upside	-57.3%	·
ZURA Zura Bio	Aug 19, 2025	HOLD	Strong Buy +160.2% avg upside 13 analysts	$2.00 63.98% Downside	+225.4%	·
GYRE Gyre Therapeutics	Aug 11, 2025	BUY	Strong Buy +210.5% avg upside 15 analysts	$25.00 276.58% Upside	-5.7%	·
RLYB Rallybio	Apr 30, 2025	HOLD	Buy +43.5% avg upside 8 analysts	—	+250.8%	·
CARM Carisma Therapeutics	Apr 04, 2025	HOLD	Buy +116900.1% avg upside 11 analysts	—	·	·
RANI Rani Therapeutics Holdings	Apr 03, 2025	BUY	Strong Buy +1110.2% avg upside 10 analysts	$9.00 1046.47% Upside	-35.4%	·
ABEO Abeona Therapeutics	Mar 21, 2025	BUY	Strong Buy +130.1% avg upside 17 analysts	$15.00 102.62% Upside	-13.6%	·
OKUR OnKure Therapeutics	May 14, 2024	HOLD	Buy +480.9% avg upside 13 analysts	$15.00 266.68% Upside	-88.7%	·
ADTX Aditxt	Sep 06, 2023	BUY	Strong Buy +2541566.7% avg upside 2 analysts	$61.00 2541566.69% Upside	·	·

🔒 36 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Mitchell Kapoor — Frequently Asked Questions

How accurate are Mitchell Kapoor's stock ratings?

Based on the calls 13Foresight could measure, about 53% of Mitchell's ratings were profitable over a one-year hold, with an average return of +5.1% per rating, or +2.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Mitchell ranked on 13Foresight?

Mitchell Kapoor is currently ranked #1427 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Mitchell cover?

Mitchell most recently has ratings on DMRA, ALMS, PALI, LEGN, SE:SOBI, EVMN, GENB, BMRN, HALO, NTLA, AVTX, RNAC and 29 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Mitchell Kapoor

Rating Distribution

Welcome to 13Foresight!